8.30 Registration and refreshments
8.50 Chairmanfs Opening Address
Focus Track 1: Protein Therapeutics
DISCOVERY, SCREENING AND DESIGN
9.00 Opening Keynote: Evolving development of next generation therapeutic antibody
by design
• Development of re-engineered, improved, whole antibody and antibody fragment-based
products
• Reduction in risk of immunogenicity by using fully human recombinant antibodies or human
antibodies derived from transgenic mice
• Update on current humanization technologies developed and how scaffolding design are
used to improve efficacy characteristics
• Upcoming trends in antibody engineering and design: concept of nanobodies
Alejandro A Aruffo, Vice President, Global Pharmaceutical Development
Abbott Bioresearch Center, USA
9.45 Case Study - Beyond Antibodies: Developing next generation biologicals from
protein scaffolds
• Overview of the concept and development of beyond antibodies
• Introduce the field of protein based scaffolds with real-world case studies
• Where are the challenges in biotherapeutics development
• Validating phylomers as a next generation class of therapeutic peptides
Paul Watt, Vice President Technology Development
Phylogica, Australia
10.30 Morning refreshments
IMPROVING, EVALUATING AND RE-ENGINEERING
11.00 Pre-clinical development and optimization of monoclonal antibodies
• Engineering and selection issues of protein therapeutics
• Criteria for pre-clinical and clinical assessment of immunogenecity
• Methods and strategies to deimmunise protein therapeutics
Stephan Fischer, Senior Vice President, Biologics Research and Strategy
Roche Pharma Research, Germany
11.45 Case study: Development of a monoclonal antibody for the treatment of B-cell
malignancies
• Proof of Concept – strategies for target identification and characterization
• Preclinical pharmacology and safety testing – immunogenicity
• Clinical Development – broadening disease application
Rosanne Dunn, Founder and Head of Clinical Development
Immune System Therapeutics, Australia
12.30 Networking luncheon & showcase session
INNOVATIVE BIOTHERAPEUTICS DEVELOPMENT IN ASIA
14.00 Case study: Moving from traditional research to advanced technology to
spearhead therapeutic antibodies development in China
• Use of proprietary technologies licensed and/or developed in-house for antibodies of better
characteristics
• Challenges faced when developing innovative technologies for higher potency therapeutic
antibodies
• Current state of biotherapeutics development in China and advantages of developing
therapeutic antibodies in China
Jian Ni, Chief Executive Officer and Chief Scientist
Human Antibodomics, China
14.30 Case study: Moving from biosimiliars to innovative therapeutics in India • Identify the driving forces for India biopharmaceuticals to move from biosimilars to
development of innovative therapeutics
• Challenges in moving away from biosimilars and strategies developed to progress towards
innovative therapeutics development
• Case studies of innovative antibodies developed by Indian biotechs
Subhra R. Chakrabarti, Head, Molecular Immunology and Drug Discovery
Shantha Biotech, India
15.00 Therapeutic protein development for a niche market with cutting edge
technologies: Case studies from Japan
• Understand the current state of therapeutic protein development in Japan
• Identify the driving force and strategies Japan pharma adopt in developing innovative
therapeutic proteins
• key challenges faced and opportunities for collaboration and partnerships to boost pipeline
Hisafumi Okabe, Head, Research Planning and Coordination
Chugai Pharmaceutical, Japan
15.30 Case study: Innovative therapeutics antibody development in Korea
• Leveraging on proprietary technological platform to achieve clinical success for its antibody
designed and developed in-house
• Novel antigen screening, lead development and manufacturing process
• Current state of biotherapeutics development in Korea and key advantages of developing
therapeutic antibodies in Korea
June-Young Park, Chief Technology and Business Development Officer
ISU Abxis, Korea
16.00 Afternoon refreshments
16.30 Interactive roundtable discussion
17.30 Chairmanfs closing remarks
Focus Track 2: Stem Cells
8.50 Chairmanfs opening remarks
Chris Mason, Director for Regenerative Medicine, Bioprocessing Unit
University College London, UK
GLOBAL OVERVIEW OF STEM CELLS THERAPY: DISCOVERIES, OPPORTUNITIES AND COMMERCIALISATION
9.00 Honorary Opening Keynote: Stem cells and regenerative medicine as next
generation therapeutics: Opportunities and challenges
• Provide a brief overview of the identification and role of stem cells
• Give an update on the progress of stem cell therapeutics to the clinic, highlighting both
opportunities and challenges
• Provide an overview of prospects for patient-specific cellular therapeutics
• Prospects for drugs to awaken and harness the activities of the patientfs own stem and
progenitor cells
Alan Colman, Executive Director
Singapore Stem Cell Consortium, Singapore
9.30 Global partnerships and alliances among stem cells companies and academics to
bring stem cells therapy into clinic
• Provide overview of stem cells research funding in Asia, Europe and USA
• Funding models for stem cells research to encourage global partnerships in stem cells
therapy
• Legislation and regulatory framework for stem cells research and development to establish
best practices among academic and industry player globally
Octavi Quintana Trias, Director, Health Research DG
European Commission, Europe
10.00 Commercialization of Stem Cells: Translating Great Science into Successful
Business
• Sources of funding for stem cells ventures
• Address issues in raising funds for stem cells ventures
• How to project stem cells technologies and innovations to investors
Greg Bonfiglio, Managing Partner
Proteus Ventures, USA
10.30 Morning refreshments
EMBRYONIC STEM CELLS
11.00 Overview of human embryonic stem cells therapy
• Recent breakthroughs in human embryonic stem cells therapy
• Challenges and opportunities in developing human embryonic stem cells therapy
• Niches for Asian stem cells players to accelerate stem cells therapy progression into clinic
Thomas Okarma, President and Chief Executive Officer
Geron, USA
11.30 Case study: stem cells research in China
• Provide an overview of stem cells research in China
• Present the latest clinical data on stem cells research and development
• Future directions of stem cell research and development in China
Ling Song Li, Chief Scientific Officer, Stem Cell Research Center
Beijing University, China
12.00 Case study: Embryonic stem cells to treat diabetes
• Describe proprietary encapsulation technologies use to generate a renewable source of
specialized cells that can be used to treat chronic cellular diseases
• Latest clinical data demonstrating functional embryonic stem cells in curing life-threatening
diseases
• Strategies in moving from proof-of-concept to clinical trials
Alan Lewis, President & Chief Executive Officer
Novocell, USA
12.30 Afternoon luncheon & showcase session
ADULT STEM CELLS
14.00 Strategies to bring a novel stem cell therapy through the regulatory process and
into the clinic: ReN001 for stable ischemic stroke, a case study
• Technology issues: ReNeuronfs c-mycER technology for cGMP stem cell scale-up:
Advantages and burdens on the regulatory process
• Preclinical issues: Understanding the appropriate GLP safety testing models and the
particular issues for stem cells
• Clinical Trials and Trial sites, what are the options and what are the difficulties?
• The Regulators: Understanding the differing concerns from National Competent Authorities
• What opportunities might lie in Asia for R&D partnerships?
John Sinden, Chief Scientific Officer
ReNeuron, UK
14.30 Asia Pacific Case study: Adult stem cells therapy for wound healing
• Expansion of adult stem cells of clinical potential from both allogenic sources
• Development of novel treatments for orthopaedic conditions, including the
commercialization of a unique adult stem cell technology aimed at the regeneration and
repair of bone and cartilage
• Strategies to successfully bring stem cells therapy into clinics leveraging on its patented
proprietary technologies
Silviu Itescu, Chief Executive Officer
Mesoblast Limited, Australia
15.00 Technologies leveraging on multi-disciplinary approach to demonstrate stem
cells therapy feasibility
• Proprietary technologies developed in the field of gene analysis, cell research and drug
discovery
• Development of technologies and reagents specific to diabetes that use somatic stem cell
that can differentiate into pancreatic beta cell in addition to muscular dystrophy
• Development of therapies for serious cardiac insufficiency and obstructive arteriosclerosis,
ischemia that uses human multipotent adipose-derived stem (hMADS) cells
Mahendra Rao, Vice President, Stem Cell Technologies
Invitrogen, USA
15.30 Case study: stem cells research in India
• Provide an overview of stem cells research in India
• Present the latest clinical data on stem cells research and development
• Future directions of stem cell research and development in India
Satish Totey, Chief Scientific Officer
Stempeutics Research Labs, India
16.00 Afternoon refreshments
16.30 Interactive roundtable discussion
17.30 Chairmanfs closing remarks
17.40 End of Day Two
©Terrapinn Ltd. MMVII